Exaggerated pulmonary arterial hypertension (PAH) is a hallmark of high-altitude pulmonary edema (HAPE). The objective of this study was therefore to investigate genetic predisposition to HAPE by analyzing PAH candidate genes in a HAPE-susceptible (HAPE-S) family and in unrelated HAPE-S mountaineers.
Materials and Methods:
Eight family members and 64 mountaineers were clinically and genetically assessed using a PAH-specific gene panel for 42 genes by next-generation sequencing.
Results:
Two otherwise healthy family members, who developed re-entry HAPE at 3640 m during childhood, carried a likely pathogenic missense mutation (c.1198T>G p.Cys400Gly) in the Janus Kinase 2 (JAK2) gene. One of them progressed to a mild form of PAH at the age of 23 years. In two of the 64 HAPE-S mountaineers likely pathogenic variants have been detected, one missense mutation in the Cytochrome P1B1 gene, and a deletion in the Histidine-Rich Glycoprotein (HRG) gene.
Conclusions:
This is the first study identifying an inherited missense mutation of a gene related to PAH in a family with re-entry HAPE showing a progression to borderline PAH in the index patient. Likely pathogenic variants in 3.1% of HAPE-S mountaineers suggest a genetic predisposition in some individuals that might be linked to PAH signaling pathways.
Get full access to this article
View all access options for this article.
References
1.
AllemannY, SartoriC, LeporiM, PierreS, MelotC, NaeijeR, ScherrerU, and MaggioriniM. (2000). Echocardiographic and invasive measurements of pulmonary artery pressure correlate closely at high altitude. Am J Physiol Heart Circ Physiol, 279:H2013–H2016.
BaniyaS, HoldenC, and BasnyatB. (2017). Reentry high altitude pulmonary edema in the Himalayas. High Alt Med Biol, 18:425–427.
4.
BärtschP, MaggioriniM, MairbäurlH, VockP, and SwensonER. (2002). Pulmonary extravascular fluid accumulation in climbers. Lancet 360:571; author reply. 571–572.
5.
BärtschP, MaggioriniM, RitterM, NotiC, VockP, and OelzO. (1991). Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med, 325:1284–1289.
6.
BärtschP, MairbäurlH, MaggioriniM, and SwensonER. (2005). Physiological aspects of high-altitude pulmonary edema. J Appl Physiol (1985), 98:1101–1110.
7.
BärtschP, and SwensonER. (2013). Clinical practice: Acute high-altitude illnesses. N Engl J Med, 368:2294–2302.
8.
BetzT, DehnertC, BärtschP, SchommerK, and MairbäurlH. (2015). Does high alveolar fluid reabsorption prevent hape in individuals with exaggerated pulmonary hypertension in hypoxia?. High Alt Med Biol, 16:283–289.
9.
BrillAK, KunzA, OttSR, GeiserT, and HeftiJP. (2012). When “high” is not very high: High altitude pulmonary edema as first manifestation of sarcoidosis-related pulmonary hypertension. High Alt Med Biol, 13:285–287.
10.
BuschT, BärtschP, PappertD, GrünigE, HildebrandtW, ElserH, FalkeKJ, and SwensonER. (2001). Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edema. Am J Respir Crit Care Med, 163:368–373.
11.
CorvinusC, BärtschP, DehnertC, HerthFJ, and GrünigE. (2010). Pulmonary hypertension in a patient with Abt-Letterer-Siwe syndrome and episodes of HAPE. Eur Respir J, 36:1212–1214.
12.
DarvinP, JoungYH, and YangYM. (2013). JAK2-STAT5B pathway and osteoblast differentiation. JAKSTAT, 2:e24931.
13.
DasBB, WolfeRR, ChanKC, LarsenGL, ReevesJT, and IvyD. (2004). High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude. Arch Pediatr Adolesc Med, 158:1170–1176.
14.
De CaterinaR, and MadonnaR. (2009). Cytochromes CYP1A1 and CYP1B1: New pieces in the puzzle to understand the biomechanical paradigm of atherosclerosis. Cardiovasc Res, 81:629–632.
15.
de Jesus PerezVA, YuanK, LyuksyutovaMA, DeweyF, OrcholskiME, ShuffleEM, MathurM, YancyL Jr., RojasV, LiCG, CaoA, AlastaloTP, KhazeniN, CimprichKA, ButteAJ, AshleyE, and ZamanianRT. (2014). Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med, 189:1260–1272.
16.
DehnertC, GrünigE, MerelesD, von LennepN, and BärtschP. (2005). Identification of individuals susceptible to high-altitude pulmonary oedema at low altitude. Eur Respir J, 25:545–551.
17.
DehnertC, LuksAM, SchendlerG, MenoldE, BergerMM, MairbäurlH, FaoroV, BaileyDM, CastellC, HahnG, VockP, SwensonER, and BärtschP. (2010). No evidence for interstitial lung oedema by extensive pulmonary function testing at 4,559 m. Eur Respir J, 35:812–820.
18.
DehnertC, WeymannJ, MontgomeryHE, WoodsD, MaggioriniM, ScherrerU, GibbsJS, and BärtschP. (2002). No association between high-altitude tolerance and the ACE I/D gene polymorphism. Med Sci Sports Exerc, 34:1928–1933.
19.
DekkerRJ, van SoestS, FontijnRD, SalamancaS, de GrootPG, VanBavelE, PannekoekH, and HorrevoetsAJ. (2002). Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2). Blood, 100:1689–1698.
20.
EldridgeMW, PodolskyA, RichardsonRS, JohnsonDH, KnightDR, JohnsonEC, HopkinsSR, MichimataH, GrassiB, FeinerJ, KurdakSS, BicklerPE, WagnerPD, and SeveringhausJW. (1996). Pulmonary hemodynamic response to exercise in subjects with prior high-altitude pulmonary edema. J Appl Physiol (1985), 81:911–921.
21.
GalièN, HoeperMM, HumbertM, TorbickiA, VachieryJL, BarberaJA, BeghettiM, CorrisP, GaineS, GibbsJS, Gomez-SanchezMA, JondeauG, KlepetkoW, OpitzC, PeacockA, RubinL, ZellwegerM, and SimonneauG; ESC Committee for Practice Guidelines (CPG). (2009). Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J, 30:2493–2537.
22.
GalièN, HumbertM, VachieryJL, GibbsS, LangI, TorbickiA, SimonneauG, PeacockA, Vonk NoordegraafA, BeghettiM, GhofraniA, Gomez SanchezMA, HansmannG, KlepetkoW, LancellottiP, MatucciM, McDonaghT, PierardLA, TrindadePT, ZompatoriM, HoeperM, AboyansV, Vaz CarneiroA, AchenbachS, AgewallS, AllanoreY, AsteggianoR, Paolo BadanoL, Albert BarberaJ, BouvaistH, BuenoH, ByrneRA, CarerjS, CastroG, ErolC, FalkV, Funck-BrentanoC, GorenfloM, GrantonJ, IungB, KielyDG, KirchhofP, KjellstromB, LandmesserU, LekakisJ, LionisC, LipGY, OrfanosSE, ParkMH, PiepoliMF, PonikowskiP, RevelMP, RigauD, RosenkranzS, VollerH, and Luis ZamoranoJ. (2016). 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J, 37:67–119.
23.
GrünigE, JanssenB, MerelesD, BarthU, BorstMM, VogtIR, FischerC, OlschewskiH, KuechererHF, and KüblerW. (2000a). Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation, 102:1145–1150.
24.
GrünigE, MerelesD, HildebrandtW, SwensonER, KüblerW, KuechererH, and BärtschP. (2000b) Stress Doppler echocardiography for identification of susceptibility to high altitude pulmonary edema. J Am Coll Cardiol, 35:980–987.
25.
GrünigE, WeissmannS, EhlkenN, FijalkowskaA, FischerC, FourmeT, GalieN, GhofraniA, HarrisonRE, HuezS, HumbertM, JanssenB, KoberJ, KoehlerR, MachadoRD, MerelesD, NaeijeR, OlschewskiH, ProvencherS, ReichenbergerF, RetailleauK, RocchiG, SimonneauG, TorbickiA, TrembathR, and SeegerW. (2009). Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: Results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation, 119:1747–1757.
26.
GuptaRK, SoreeP, DesirajuK, AgrawalA, and SinghSB. (2017). Subclinical pulmonary dysfunction contributes to high altitude pulmonary edema susceptibility in healthy non-mountaineers. Sci Rep, 7:14892.
27.
HinderhoferK, FischerC, PfarrN, Szamalek-HoegelJ, LichtblauM, NagelC, EgenlaufB, EhlkenN, and GrünigE. (2014). Identification of a new intronic BMPR2-mutation and early diagnosis of heritable pulmonary arterial hypertension in a large family with mean clinical follow-up of 12 years. PLoS One, 9:e91374.
28.
HoustonCS, HarrisDE, and ZemanEJ. (2005). Going Higher: Oxygen, Man and Mountains. Little, Brown, Seattle, WA.
29.
HultgrenHN. (1996). High-altitude pulmonary edema: Current concepts. Annu Rev Med, 47:267–284.
30.
HultgrenHN, GroverRF, and HartleyLH. (1971). Abnormal circulatory responses to high altitude in subjects with a previous history of high-altitude pulmonary edema. Circulation, 44:759–770.
31.
HultgrenHN, SpickardWB, HellriegelK, and HoustonCS. (1961). High altitude pulmonary edema. Medicine (Baltimore), 40:289–313.
32.
HumbertM, MontiG, BrenotF, SitbonO, PortierA, Grangeot-KerosL, DurouxP, GalanaudP, SimonneauG, and EmilieD. (1995). Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med, 151:1628–1631.
33.
JanmaatML, HeerkensJL, de BruinAM, KlousA, de WaardV, and de VriesCJ. (2010). Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood, 115:1453–1460.
34.
KanerRJ, LadettoJV, SinghR, FukudaN, MatthayMA, and CrystalRG. (2000). Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol, 22:657–664.
35.
KircherM, WittenDM, JainP, O'RoakBJ, CooperGM, and ShendureJ. (2014). A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet, 46:310–315.
36.
KralovicsR, PassamontiF, BuserAS, TeoSS, TiedtR, PasswegJR, TichelliA, CazzolaM, and SkodaRC. (2005). A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 352:1779–1790.
37.
KwapiszewskaG, JohansenAKZ, Gomez-ArroyoJ, and VoelkelNF. (2019). Role of the Aryl hydrocarbon receptor/ARNT/cytochrome P450 system in pulmonary vascular diseases. Circ Res, 125:356–366.
LorenzoVF, YangY, SimonsonTS, NussenzveigR, JordeLB, PrchalJT, and GeRL. (2009). Genetic adaptation to extreme hypoxia: Study of high-altitude pulmonary edema in a three-generation Han Chinese family. Blood Cells Mol Dis, 43:221–225.
40.
LuksAM. (2014). A novel risk factor for high altitude pulmonary edema?. Wilderness Environ Med, 25:490–492.
41.
MachadoRD, SouthgateL, EichstaedtCA, AldredMA, AustinED, BestDH, ChungWK, BenjaminN, ElliottCG, EyriesM, FischerC, GrafS, HinderhoferK, HumbertM, KeilesSB, LoydJE, MorrellNW, NewmanJH, SoubrierF, TrembathRC, VialesRR, and GrünigE. (2015). Pulmonary arterial hypertension: A current perspective on established and emerging molecular genetic defects. Hum Mutat, 36:1113–1127.
42.
MacInnisMJ, and KoehleMS. (2016). Evidence for and against genetic predispositions to acute and chronic altitude illnesses. High Alt Med Biol, 17:281–293.
43.
MaggioriniM. (2006). High altitude-induced pulmonary oedema. Cardiovasc Res, 72:41–50.
44.
MaggioriniM, Brunner-La RoccaHP, PethS, FischlerM, BohmT, BernheimA, KienckeS, BlochKE, DehnertC, NaeijeR, LehmannT, BärtschP, and MairbäurlH. (2006). Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: A randomized trial. Ann Intern Med, 145:497–506.
45.
NaeijeR, De BackerD, VachieryJL, and De VuystP. (1996). High-altitude pulmonary edema with primary pulmonary hypertension. Chest, 110:286–289.
46.
NiCW, HsiehHJ, ChaoYJ, and WangDL. (2004). Interleukin-6-induced JAK2/STAT3 signaling pathway in endothelial cells is suppressed by hemodynamic flow. Am J Physiol Cell Physiol, 287:C771–C780.
47.
OlssonAK, LarssonH, DixeliusJ, JohanssonI, LeeC, OelligC, BjorkI, and Claesson-WelshL. (2004). A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res, 64:599–605.
48.
PaulinR, MelocheJ, and BonnetS. (2012). STAT3 signaling in pulmonary arterial hypertension. JAKSTAT, 1:223–233.
49.
PoonIK, PatelKK, DavisDS, ParishCR, and HulettMD. (2011). Histidine-rich glycoprotein: The Swiss Army knife of mammalian plasma. Blood, 117:2093–2101.
50.
RichardsS, AzizN, BaleS, BickD, DasS, Gastier-FosterJ, GrodyWW, HegdeM, LyonE, SpectorE, VoelkerdingK, and Rehm HL; ACMG Laboratory Quality AssuranceCommittee. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med, 17:405–424.
51.
RoachJM, and SchoeneRB. (2002). High-altitude pulmonary edema. In: Medical Aspects of Harsh Environments. KB Pandoff and RE Burr, eds. Department of the Army, Washington, DC. p. 644.
52.
ScogginCH, HyersTM, ReevesJT, and GroverRF. (1977). High-altitude pulmonary edema in the children and young adults of Leadville, Colorado. N Engl J Med, 297:1269–1272.
53.
SimonneauG, MontaniD, CelermajerDS, DentonCP, GatzoulisMA, KrowkaM, WilliamsPG, and SouzaR. (2019). Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J, 53:1801913.
54.
SongJ, EichstaedtCA, Rodriguez VialesR, BenjaminN, HarutyunovaS, FischerC, GrünigE, and HinderhoferK. (2016). Identification of genetic defects in pulmonary arterial hypertension by a new panel diagnostic. Clin Sci (Lond), 22:2043–2052.
55.
ValiP, and LakshminrusimhaS. (2017). The fetus can teach us: Oxygen and the pulmonary vasculature. Children (Basel), 4:e67.
56.
WestJ, CoganJ, GeraciM, RobinsonL, NewmanJ, PhillipsJA, LaneK, MeyrickB, and LoydJ. (2008). Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics, 1:45.
57.
WhiteK, JohansenAK, NilsenM, CiuclanL, WallaceE, PatonL, CampbellA, MorecroftI, LoughlinL, McClureJD, ThomasM, MairKM, and MacLeanMR. (2012). Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation, 126:1087–1098.
58.
YangP, ZhangY, PangJ, ZhangS, YuQ, HeL, WagnerKU, ZhouZ, and WangCY. (2013). Loss of Jak2 impairs endothelial function by attenuating Raf-1/MEK1/Sp-1 signaling along with altered eNOS activities. Am J Pathol, 183:617–625.
59.
YangYZ, WangYP, XuJ, and GeRL. (2017). The susceptibility gene screening in a Chinese high-altitude pulmonary edema family by whole-exome sequencing. Yi Chuan, 39:135–142.
60.
YuhongL, TanaW, ZhengzhongB, FengT, QinG, YingzhongY, WeiG, YapingW, LangelierC, RondinaMT, and GeRL. (2018). Transcriptomic profiling reveals gene expression kinetics in patients with hypoxia and high altitude pulmonary edema. Gene, 651:200–205.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
